Pfizer on Monday said it had discontinued the development of the experimental weight-loss pill danuglipron after a trial patient experienced a potential drug-induced liver injury, which resolved ...

The Pfizer logo on its building in New York City. (CARLO ALLEGRI/REUTERS) Pfizer is struggling to find its way after the pandemic. When Covid-19 hit, the pharmaceutical giant’s vaccine and drug ...

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. (AP Photo/Mark Lennihan, File) A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Pfizer Helped Save the World With Covid Vaccines. Now It Needs to Right Itself. The company is pulling back on some of its research programs and laying off workers after overestimating pandemic ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N) said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it.

Pfizer said on Wednesday its experimental gene therapy for Duchenne muscular dystrophy (DMD) failed to improve the motion function of patients in a late-stage trial compared with a placebo.

Pfizer is shelving development of a twice-daily version of its weight loss drug after a trial proved users reported high rates of adverse side effects.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York.